ClinicalTrials.gg
Not yet recruitingNCT07861581Updated Oct 6, 2026

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of QLS2312 Injection

A Phase 1 interventional study of QLS2312 Injection and Placebo in Healthy Participants Study, sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Shanghai Qilu Pharmaceutical Research and Development Center LTD (part of Qilu Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a first-in-human Phase 1 clinical study conducted in healthy adult participants in China to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of QLS2312 Injection after single and multiple subcutaneous administrations. The study consists of Part A and Part B: Part A is a single-ascending-dose study, and Part B is a multiple-ascending-dose (MAD) study.

02

Conditions studied

  • Healthy Participants Study
03

In context

Lead sponsor

Shanghai Qilu Pharmaceutical Research and Development Center LTD is the lead sponsor of 8 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand and comply with the study procedures, voluntarily participate in this trial, and sign the form.
  2. Aged 18-55 years, inclusive.
  3. Body weight ≥50 kg for males and ≥45 kg for females; (BMI) 18.5-28.0 kg/m², inclusive.
  4. Serum IgA, IgG, and IgM are within the normal reference range.
  5. Medical history review, physical examination, laboratory tests, vital signs, imaging examinations, etc. are normal, or are judged by the investigator as abnormal but not .
  6. From signing the informed consent form until the end of the trial or within 3 months after the last dose of the product, whichever is longer: no plan to donate sperm or eggs, no plan for pregnancy, and willingness to use effective .

Exclusion criteria

Exclusion Criteria:

  1. History of definite food or drug allergy, or known allergy to the product or its .
  2. Prior use of any biologic targeting APRIL or MASP-2.
  3. Use of any prescription or non-prescription drug within 14 days before Screening, or still within 5 half-lives of the drug before Screening, whichever is longer.
  4. Use of other therapeutic biologics within 1 month before Screening; or still within 5 half-lives of the drug before Screening, whichever is longer.
  5. Blood donation/blood loss >400 mL within 3 months before Screening, or >200 mL within 4 weeks before Screening.
  6. Average daily smoking of more than 5 cigarettes per day within 3 months before Screening.
  7. Weekly alcohol intake exceeding 14 units of alcohol within 3 months before Screening - or positive alcohol breath test on D-1.
  8. History of drug abuse within 5 years before Screening, or positive urine drug screen on D-1.
  9. History of active tuberculosis, or positive tuberculosis screening at Screening.
  10. History of fainting during needle insertion or blood draw, or difficult blood collection.
  11. Severe infection within 1 month before Screening; or hospitalization due to infection, or receipt of systemic antibiotics/antiviral therapy, within 1 month before Screening.
  12. Surgery within 3 months before Screening, or planned surgery of Grade 2 or above as defined in the Medical Institution Surgical Procedure Classification Management Measures during the study.
  13. corrected by Fridericia's formula (QTcF) ≥450 ms for males or ≥460 ms for females at Screening or on D-1.
  14. Positive surface antigen (HBsAg), virus antibody (HCV Ab), Treponema pallidum-specific antibody, or antibody (HIV Ab) at Screening.
  15. Presence of a disease that the investigator judges may affect the pharmacokinetic characteristics of the investigational product.
  16. Pregnant or lactating women, or positive pregnancy test at Screening or on D-1.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    QLS2312 Injection

    Drug: QLS2312 Injection

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugQLS2312 Injection

    QLS2312 Injection to be administered by SC injection

  • DrugPlacebo

    Placebo solution to be administered at a matching volume by SC injection

06

What researchers measure

Primary outcomes

  1. Incidence, severity, and relationship to treatment of treatment-emergent adverse events (TEAEs)

    Time frame: 0-169 days

Secondary outcomes

  1. Maximum serum concentration (Cmax)

    Time frame: 0-169 days

  2. Area Under The Curve Extrapolated To Infinity (AUCinf)

    Time frame: 0-169 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Oct 2027, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartEst.
Nov 11, 2026
Primary completionEst.
Oct 9, 2027
CompletionEst.
Nov 20, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07861581
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Nov 11, 2026 (estimated)
Primary completion
Oct 9, 2027 (estimated)
Completion
Nov 20, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Zhang Rui
Contact
zrlw2001@126.com
+86 18560087298
Xu Feng
Contact
xufengsdu@126.com
+86 18560083066

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion